Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic.


Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 22 07 2021
accepted: 08 11 2021
pubmed: 8 1 2022
medline: 19 3 2022
entrez: 7 1 2022
Statut: ppublish

Résumé

A personalized approach to prevention and early detection based on known risk factors should contribute to early diagnosis and treatment of breast cancer. We initiated a risk assessment clinic for all women wishing to undergo an individual breast cancer risk assessment. Women underwent a complete breast cancer assessment including a questionnaire, mammogram with evaluation of breast density, collection of saliva sample, consultation with a radiologist, and a breast cancer specialist. Women aged 40 or older, with 0 or 1 first-degree relative with breast cancer diagnosed after the age of 40 were eligible for risk assessment using MammoRisk, a machine learning-based tool that provides an individual 5-year estimated risk of developing breast cancer based on the patient's clinical data and breast density, with or without polygenic risk scores (PRSs). DNA was extracted from saliva samples for genotyping of 76 single-nucleotide polymorphisms. The individual risk was communicated to the patient, with individualized screening and prevention recommendations. A total of 290 women underwent breast cancer assessment, among which 196 women (68%) were eligible for risk assessment using MammoRisk (median age 52, range 40-72). When PRS was added to MammoRisk, 40% (n = 78) of patients were assigned a different risk category, with 28% (n = 55) of patients changing from intermediate to moderate or high risk. Individual risk assessment is feasible in the general population. Screening recommendations could be given based on individual risk. The use of PRS changed the risk score and screening recommendations in 40% of women.

Identifiants

pubmed: 34994879
doi: 10.1007/s10549-021-06445-8
pii: 10.1007/s10549-021-06445-8
pmc: PMC8739506
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

375-383

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

JAMA. 2019 Sep 3;322(9):857-867
pubmed: 31479144
Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):715-22
pubmed: 15159301
Breast Cancer Res. 2019 May 22;21(1):68
pubmed: 31118087
Breast Cancer Res Treat. 2016 Oct;159(3):513-25
pubmed: 27565998
NPJ Breast Cancer. 2017 Sep 13;3:34
pubmed: 28944288
N Engl J Med. 2007 Jan 18;356(3):227-36
pubmed: 17229950
Nat Rev Clin Oncol. 2020 Nov;17(11):687-705
pubmed: 32555420
Breast Cancer Res Treat. 2015 Jan;149(2):517-23
pubmed: 25575444
Nat Genet. 2020 Jun;52(6):572-581
pubmed: 32424353
PLoS One. 2017 Jan 20;12(1):e0168601
pubmed: 28107349
J Natl Cancer Inst. 1997 May 21;89(10):731
pubmed: 9168189
Genet Med. 2016 Dec;18(12):1190-1198
pubmed: 27464310
Am J Hum Genet. 2003 May;72(5):1117-30
pubmed: 12677558
Radiology. 2004 Jan;230(1):29-41
pubmed: 14617762
Lancet Oncol. 2005 Oct;6(10):798-808
pubmed: 16198986
Breast Cancer Res Treat. 2015 Apr;150(2):415-26
pubmed: 25744293
J Natl Cancer Inst. 1999 Sep 15;91(18):1541-8
pubmed: 10491430
Bull Cancer. 2020 Oct;107(10):972-981
pubmed: 32977936
Nat Commun. 2020 Jul 31;11(1):3833
pubmed: 32737321
Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
J Clin Oncol. 2015 Mar 10;33(8):923-9
pubmed: 25624442
Breast. 2017 Dec;36:89-95
pubmed: 28988610
J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86
pubmed: 2593165
J Natl Cancer Inst. 2020 Sep 1;112(9):893-901
pubmed: 31899501
Ann Oncol. 2019 May 1;30(5):781-787
pubmed: 30887043
Nat Genet. 2013 Apr;45(4):353-61, 361e1-2
pubmed: 23535729
J Natl Cancer Inst. 2015 Apr 08;107(5):
pubmed: 25855707
Breast Cancer Res. 2012 Feb 07;14(1):R25
pubmed: 22314178
Eur Radiol. 2019 Jul;29(7):3830-3838
pubmed: 30770972
Stat Med. 2004 Apr 15;23(7):1111-30
pubmed: 15057881
Eur J Cancer. 2021 Mar;146:30-47
pubmed: 33578357
Br J Cancer. 2004 Oct 18;91(8):1580-90
pubmed: 15381934
J Natl Cancer Inst. 2021 Sep 4;113(9):1168-1176
pubmed: 33769540
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Prog Mol Biol Transl Sci. 2017;151:1-32
pubmed: 29096890
Breast Cancer Res. 2010;12(3):R28
pubmed: 20482762
J Natl Cancer Inst. 2020 Mar 1;112(3):278-285
pubmed: 31165158
Br J Cancer. 2014 Jan 21;110(2):535-45
pubmed: 24346285
Am J Hum Genet. 1998 Jan;62(1):145-58
pubmed: 9443863
Nature. 2007 Jun 28;447(7148):1087-93
pubmed: 17529967
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1159-69
pubmed: 16775176
N Engl J Med. 2005 Jul 21;353(3):229-37
pubmed: 16034008
Breast Cancer Res. 2016 Dec 8;18(1):124
pubmed: 27931260
Ann Intern Med. 2012 May 1;156(9):635-48
pubmed: 22547473
Br J Cancer. 2013 Jun 11;108(11):2205-40
pubmed: 23744281
Am J Hum Genet. 1991 Feb;48(2):232-42
pubmed: 1990835
Br J Cancer. 2008 Apr 22;98(8):1457-66
pubmed: 18349832
Breast Cancer Res Treat. 2019 Jul;176(1):141-148
pubmed: 30941651

Auteurs

Mahasti Saghatchian (M)

American Hospital of Paris, Neuilly-sur-Seine, France. mahasti.saghatchian@ahparis.org.
Paris-Descartes University, Paris, France. mahasti.saghatchian@ahparis.org.

Marc Abehsera (M)

American Hospital of Paris, Neuilly-sur-Seine, France.

Amina Yamgnane (A)

American Hospital of Paris, Neuilly-sur-Seine, France.

Caroline Geyl (C)

American Hospital of Paris, Neuilly-sur-Seine, France.

Emilien Gauthier (E)

Predilife, Villejuif, France.

Valérie Hélin (V)

Predilife, Villejuif, France.

Matéo Bazire (M)

Institut Curie, Paris, France.

Laure Villoing-Gaudé (L)

Institut Curie, Paris, France.

Cécile Reyes (C)

Institut Curie, Paris, France.

David Gentien (D)

Institut Curie, Paris, France.

Lisa Golmard (L)

INSERM U830 D.R.U.M. Team, Institut Curie Hospital, Paris-University, Paris, France.

Dominique Stoppa-Lyonnet (D)

Institut Curie, Paris, France.
INSERM U830 D.R.U.M. Team, Institut Curie Hospital, Paris-University, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH